Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: All Mtn Ski who wrote (303)	9/16/1998 12:07:00 PM
From: All Mtn Ski	Read Replies (1) \| Respond to of 548

The Full Story: Baxter sets Q3 charges, drops HemAssist product DEERFIELD, Ill., Sept 16 (Reuters) - Baxter Healthcare Corp. <BAX.N> said Wednesday it would take third quarter charges of $178 million related to breast implant litigation and $75 million to drop development of its blood substitute product, HemAssist, which is derived from human hemoglobin. The company also said it anticipates taking a third-quarter charge against net earnings of about $40 million, primarily for the write down of certain minority investments and the dissolution of certain joint ventures. The company said it has decided to focus its research-and-development efforts in oxygen-carrying therapeutics, or "blood substitutes," on its second-generation program, which is based on genetically engineered hemoglobin molecules. Ending its development of HemAssist will force the company to eliminate about 100 jobs worldwide. The company said it would offer some of those employees jobs developing the second generation program or in its other businesses. Baxter halted its Phase III U.S. clinical trial of HemaAssist in February because it noticed higher mortality rates among patients using HemaAssist than those given a placebo, prompting Baxter to determine the results to be inconclusive, Baxter spokeswoman, Mary Thomas said. She said The company halted the European clincal trial of the product in June because of concerns about the drug's safety and efficacy. Baxter said in its statement that it will modify its manufacturing facility in Neuchatel, Switzerland, which was designed to manufacture a human hemoglobin product, to produce other Baxter biopharmaceutical products. While we're disappointed, delays are sometimes part of the process of developing breakthrough medical therapies such as oxygen-carrying therapeutics," said Harry Jansen Kraemer, Baxter's president. Kraemer described halting the development of HemAssist as "a difficult decision," but said it wasn't clear whether its market value would have outweighed development costs. First call analysts' consensus put Baxter's earnings at $0.61 per share for the third quarter. ((--Elizabeth Smith, New York newsroom, 212-859-1700)) (Reuters 10:11 AM ET 09/16/98) For the full text story, see infobeat.com

To: All Mtn Ski who wrote (303)	11/19/1998 7:35:00 AM
From: TokyoMex	Read Replies (1) \| Respond to of 548

==================NoBlood! News Alert====================== NoBlood! - The Bloodless Medicine and Surgery Network November 18, 1998 This News Alert may be redistributed by email only in its original form. Read the full-text articles on the World Wide Web at: noblood.com ============================================================ NEWS FLASH: The US Government Validates Bloodless Medicine! noblood.com The Veteran's Administration has added bloodless surgical protocols for their arsenal. WEB INSIGHTS: Maximizing the Internet as a Resource noblood.com Get the most out of this valuable resource with the least amount of time and energy. IN-DEPTH REPORT: Radical Retropubic Prostatectomy With Minimal Blood Loss noblood.com Since 1992, radical retropubic prostatectomy (RRP) has become the open surgical procedure most frequently performed by urologists. DID YOU KNOW?: Frequently Asked Questions Concerning Medical Emergencies noblood.com Read through some frequently asked questions that others have posed. The answers provided regarding your options in a medical crisis may help you as well. NEWS FLASH: Alliance Pharmaceutical Corp. Announces Major Clinical Advancements With the Commencement of Phase 3 LiquiVent Trial, Phase 3 Oxygent Trial, and FloGel Pilot Trial noblood.com The company now has all three of its lead products in Phase 3 clinical development. FEATURED LINK: Study: Hepatitis C may trigger jump in need for liver transplants cnn.com More than a five-fold increase in the demand for liver transplants over the next decade. NEWS FLASH: Vietnam Era Veterans May Be at Greater Risk for Hepatitis C noblood.com Heavy transfusion activity during the Vietnam War. PUBLIC LECTURE: Author Judith Reitman to Lecture at Legacy Portland Hospital noblood.com Ms. Reitman discusses the status of blood safety on her Red Cross expose tour. NEWS FLASH: Opening Arguments Will Begin in New Orleans Against Four Pharmaceutical Companies noblood.com Pharmaceutical companies may have knowingly sold AIDS-tainted blood products to Hemophiliacs. NOW DISCUSSING: Thrombocythaemia discussions.noblood.com It is a kind of blood disease and recently it is becoming more like leukemia because of a very low hemoglobin. =============================================================== Discussion Forums - noblood.com =============================================================== General: Patients and professionals interactively exchange healthcare information. Browser - discussions.noblood.com NewsReader - news://news.noblood.com/noblood.public.general Coordinators: Peer discussions involving matters relating to coordinators. Browser - discussions.noblood.com NewsReader - news://news.noblood.com/noblood.public.coordinators ============================================================= News Alert! Forward to a colleague! ============================================================= Sign up to receive NoBlood! News Alert. noblood.com We monitor and deliver bloodless healthcare news to your inbox. To subscribe click here noblood.com or forward this to newsalert@noblood.com with "SUBSCRIBE" in the subject. To unsubscribe, reply with "UNSUBSCRIBE" in the subject. To change your information click here noblood.com ============================================================= Contact us at: ============================================================= admin@noblood.com editors@noblood.com hospitals@noblood.com products@noblood.com professionals@noblood.com sponsors@noblood.com techsupport@noblood.com or Post a Talk Back from any page! noblood.com This News Alert may be redistributed by email only in its original form. ============================================================= (Copyright © 1996-1998 CollabNet Inc.) ALL RIGHTS RESERVED Terms under which this information is provided to you. noblood.com